This Biotech Stock Down 20% Is Ready To Reverse Course

October 26, 2022
Health Care

This biotech stock has been completely ignored by most retail investors.

That is because their core products are focused on medicine and vaccinations for pets & livestock.

If you’re not familiar with the market, the global animal health care market was last valued at $45 billion in 2020 and is expected to grow annually by 9% from 2022 to 2028.

The reason for this massive opportunity in growth is largely due to a significant rise in demand for protein based foods and food-borne diseases globally.

Pair that with COVID likely stemming from an animal, and the market opportunity for this unique sector within healthcare is much bigger than most investors realize.

And after reporting a very impressive earnings call yesterday, this stock looks ready to be one of the top healthcare stocks over the next few years.

So who are they?

What’s our price target?

And what’s the catalyst needed for this stock to blow up?

Start your investment journey

Scan to download Moby

Scan to download Moby

Annual

Want the full Moby experience? Our annual premium offers news, alerts, earnings, IPO calendars and more, including the Ultimate Investing Course (at a value of $99.99USD) to help you invest smarter. Save 45% with our Annual Premium – billed at $199.95 USD/year.

$0 / 7days

$16.66 USD/month

Download for Free

Monthly

Ready to start making better investment decisions? Join our monthly premium today with access to research, reports, and more for only $29.95USD.

$29.95 / month

+ processing fees

Try Monthly